Typos spark social media backlash

Posted 11 April 2025 PM 

News of a product alert that started with a couple of typos and spiralled into complaints to the TGA about adverse events and drug efficacy was our top story this week.

The typographical errors on multiple strengths of Takeda's in-demand ADHD Vyvanse, hit social media and snowballed into concerns that the drug was no longer working with the TGA hit with an increase in reports of suspected adverse events.

To see the whole article, please login